LEAPER RNA editing therapy(Edigene)

N/A

Report date: 2024/08/16 17:31:20

Base Information

Drug NameLEAPER RNA editing therapy(Edigene)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionRNA modulators
TargetsRibonucleic Acid
Therapy Area/IndicationsUsher Syndromes, 2alpha 1-Antitrypsin DeficiencyMuscular Dystrophy, Duchenne
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesEdigene Inc
China Registration ClassN/A

Develop Information

Active CompaniesEdigene Inc
Inactive CompaniesN/A
Active IndicationsUsher Syndromes, 2alpha 1-Antitrypsin DeficiencyMuscular Dystrophy, Duchenne
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A